Molecular subgroups of medulloblastoma: the current consensus - PubMed (original) (raw)
. 2012 Apr;123(4):465-72.
doi: 10.1007/s00401-011-0922-z. Epub 2011 Dec 2.
Paul A Northcott, Andrey Korshunov, Marc Remke, Yoon-Jae Cho, Steven C Clifford, Charles G Eberhart, D Williams Parsons, Stefan Rutkowski, Amar Gajjar, David W Ellison, Peter Lichter, Richard J Gilbertson, Scott L Pomeroy, Marcel Kool, Stefan M Pfister
Affiliations
- PMID: 22134537
- PMCID: PMC3306779
- DOI: 10.1007/s00401-011-0922-z
Molecular subgroups of medulloblastoma: the current consensus
Michael D Taylor et al. Acta Neuropathol. 2012 Apr.
Abstract
Medulloblastoma, a small blue cell malignancy of the cerebellum, is a major cause of morbidity and mortality in pediatric oncology. Current mechanisms for clinical prognostication and stratification include clinical factors (age, presence of metastases, and extent of resection) as well as histological subgrouping (classic, desmoplastic, and large cell/anaplastic histology). Transcriptional profiling studies of medulloblastoma cohorts from several research groups around the globe have suggested the existence of multiple distinct molecular subgroups that differ in their demographics, transcriptomes, somatic genetic events, and clinical outcomes. Variations in the number, composition, and nature of the subgroups between studies brought about a consensus conference in Boston in the fall of 2010. Discussants at the conference came to a consensus that the evidence supported the existence of four main subgroups of medulloblastoma (Wnt, Shh, Group 3, and Group 4). Participants outlined the demographic, transcriptional, genetic, and clinical differences between the four subgroups. While it is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, herein we outline the current consensus nomenclature, and the differences between the medulloblastoma subgroups.
Figures
Fig. 1
Dendrogram depicting the classification of embryonal tumors of the cerebellum. Medulloblastomas should be differentiated from the less common ATRTs and ETANTRs of the cerebellum. Under the current consensus classification of medulloblastoma four principle subgroups are identified: Wnt, Shh, Group 3, and Group 4. The evidence suggests that each of the four principle subgroups will likely have distinct ‘subsets’ that are biologically and clinically homogeneous as compared to other subsets from within the same subgroup. As the nature and number of subsets for each subgroup are currently unknown, the consensus classification suggests that each subset be named using a Greek letter (α, β, γ, etc.) until such time as they are sufficiently characterized to be named based on their molecular etiology
Fig. 2
Comparison of the various subgroups of medulloblastoma including their affiliations with previously published papers on medulloblastoma molecular subgrouping
Similar articles
- Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T, Shirsat N, Jalali R. Gupta T, et al. Curr Pediatr Rev. 2015;11(2):106-19. doi: 10.2174/1573396311666150702104030. Curr Pediatr Rev. 2015. PMID: 26133181 Review. - Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott PA, Gajjar A, Robinson GW, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister SM, Taylor MD, Pomeroy SL. Ramaswamy V, et al. Acta Neuropathol. 2016 Jun;131(6):821-31. doi: 10.1007/s00401-016-1569-6. Epub 2016 Apr 4. Acta Neuropathol. 2016. PMID: 27040285 Free PMC article. Review. - Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC, Lindsey JC, Straughton D, Hogg TL, Cole M, Megahed H, Ryan SL, Lusher ME, Taylor MD, Gilbertson RJ, Ellison DW, Bailey S, Clifford SC. Schwalbe EC, et al. Clin Cancer Res. 2011 Apr 1;17(7):1883-94. doi: 10.1158/1078-0432.CCR-10-2210. Epub 2011 Feb 16. Clin Cancer Res. 2011. PMID: 21325292 Free PMC article. - Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study.
Schwalbe EC, Lindsey JC, Nakjang S, Crosier S, Smith AJ, Hicks D, Rafiee G, Hill RM, Iliasova A, Stone T, Pizer B, Michalski A, Joshi A, Wharton SB, Jacques TS, Bailey S, Williamson D, Clifford SC. Schwalbe EC, et al. Lancet Oncol. 2017 Jul;18(7):958-971. doi: 10.1016/S1470-2045(17)30243-7. Epub 2017 May 22. Lancet Oncol. 2017. PMID: 28545823 Free PMC article. - Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, Mynarek M, Rutkowski S, Robinson GW, Gajjar A, Cavalli F, Ramaswamy V, Taylor MD, Lindsey JC, Hill RM, Jäger N, Korshunov A, Hicks D, Bailey S, Kool M, Chavez L, Northcott PA, Pfister SM, Clifford SC. Sharma T, et al. Acta Neuropathol. 2019 Aug;138(2):309-326. doi: 10.1007/s00401-019-02020-0. Epub 2019 May 10. Acta Neuropathol. 2019. PMID: 31076851 Free PMC article.
Cited by
- Case report: A case study of variant calling pipeline selection effect on the molecular diagnostics outcome.
Skitchenko R, Smirnov S, Krapivin M, Smirnova A, Artomov M, Loboda A, Dinikina Y. Skitchenko R, et al. Front Oncol. 2024 Oct 31;14:1422811. doi: 10.3389/fonc.2024.1422811. eCollection 2024. Front Oncol. 2024. PMID: 39544296 Free PMC article. - Advances in CAR-T therapy for central nervous system tumors.
Zhou D, Zhu X, Xiao Y. Zhou D, et al. Biomark Res. 2024 Nov 6;12(1):132. doi: 10.1186/s40364-024-00679-6. Biomark Res. 2024. PMID: 39506843 Free PMC article. Review. - Copy number variation heterogeneity reveals biological inconsistency in hierarchical cancer classifications.
Yang Z, Carrio-Cordo P, Baudis M. Yang Z, et al. Mol Cytogenet. 2024 Nov 6;17(1):26. doi: 10.1186/s13039-024-00692-2. Mol Cytogenet. 2024. PMID: 39506842 Free PMC article. - Transcriptomic landscape identifies two unrecognized ependymoma subtypes and novel pathways in medulloblastoma.
Arora S, Nuechterlein N, Jensen M, Glatzer G, Sievers P, Varadharajan S, Korshunov A, Sahm F, Mack SC, Taylor MD, Holland EC. Arora S, et al. bioRxiv [Preprint]. 2024 Oct 22:2024.10.21.619495. doi: 10.1101/2024.10.21.619495. bioRxiv. 2024. PMID: 39484476 Free PMC article. Preprint. - Risk-Stratified Radiotherapy in Pediatric Cancer.
Upadhyay R, Paulino AC. Upadhyay R, et al. Cancers (Basel). 2024 Oct 18;16(20):3530. doi: 10.3390/cancers16203530. Cancers (Basel). 2024. PMID: 39456624 Free PMC article. Review.
References
- Al-Halabi H, Nantel A, Klekner A, Guiot MC, Albrecht S, Hauser P, Garami M, Bognar L, Kavan P, Gerges N, Shirinian M, Roberge D, Muanza T, Jabado N. Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastoma. Acta Neuropathol. 2011;121:229–239. doi: 10.1007/s00401-010-0780-0. - DOI - PubMed
- Bale SJ, Falk RT, Rogers GR. Patching together the genetics of Gorlin syndrome. J Cutan Med Surg. 1998;3:31–34. - PubMed
- Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ, Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790–13795. doi: 10.1073/pnas.191502998. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- R01 CA129541/CA/NCI NIH HHS/United States
- R01 NS055089/NS/NINDS NIH HHS/United States
- R01 CA129541-05/CA/NCI NIH HHS/United States
- R01 CA109467/CA/NCI NIH HHS/United States
- 13457/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources